Alkermes plc
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Blair Jackson
- Full Time Employees
- 2,050
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Connaught House Dublin DU Ireland D04 C5Y6
- IPO Date
- Jul 16, 1991
- CIK
- 0001520262
- Website
- alkermes.com
- Similar Companies
- Business
- Alkermes plc (Nasdaq: ALKS) develops, manufactures and commercializes treatments for central nervous system (CNS) disorders, addiction and oncology. The company offers proprietary products including Vivitrol (extended-release naltrexone injection) for alcohol and opioid use disorders; Aristada and Aristada Initio (aripiprazole lauroxil) for schizophrenia; Lybalvi (olanzapine and samidorphan) for schizophrenia and bipolar I disorder; and Alkermes' oncology portfolio featuring Nemvaleukin alfa, a novel interleukin-2 variant cytokine in clinical development for advanced solid tumors. Alkermes provides contract development and manufacturing services through its Alkermes Pharma subsidiary, specializing in drug formulation, aseptic fill-finish and particle engineering for complex injectable and inhaled therapeutics. Founded in 1987 and headquartered in Waltham, Massachusetts, the company operates primarily in the United States and Ireland, with commercial activities focused on specialty pharmaceuticals for healthcare providers, payers and patients in neurology, addiction and cancer treatment markets. In 2024, Alkermes advanced its oncology pipeline by initiating a Phase 3 clinical trial for nemvaleukin alfa in melanoma following positive Phase 2 data; completed a strategic licensing agreement with Janssen Biotech for a novel CD38-targeting antibody-drug conjugate; and reported a $200 million milestone payment from a prior collaboration while optimizing its neuroscience portfolio through cost-saving measures amid patent expirations.
Company News
Financial Review: C4 Therapeutics (NASDAQ:CCCC) and Alkermes (NASDAQ:ALKS)
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000
Why Is Alkermes (ALKS) Up 1.7% Since Last Earnings Report?
Alkermes (NASDAQ:ALKS) Stock Price Passes Above Two Hundred Day Moving Average – Here’s What Happened
The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
Bank of America Corp DE Trims Position in Alkermes plc $ALKS
ALKS Stock Rises 27% in 3 Months: Here's What You Should Know
Alkermes plc $ALKS Shares Sold by Glenmede Trust Co. NA
Alkermes plc (ALKS) Q2 2026 Earnings Call Transcript
Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down
Compared to Estimates, Alkermes (ALKS) Q2 Earnings: A Look at Key Metrics
Alkermes Q2 Earnings Call Highlights
Alkermes (ALKS) Reports Break-Even Earnings for Q2
Alkermes plc Reports Second Quarter 2026 Financial Results
Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Alkermes to Report Second Quarter Financial Results on July 28, 2026
Alkermes' Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis
Biotech ETF Index Surges 10% After Rebalance
Alkermes PLC (ALKS) Shares Surge 4.3% -- What GF Score of 70 Tells Investors
Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton